Exosomes: Bio-trash to Bio-treasure We’ve all heard the phrase “One man’s trash is another man’s treasure.” It turns out that what often holds true for the antique business sometimes holds true for biotech as well. This WEEKLY shows how. Term of the Week: Exosome...
Proteasomes to the Rescue Many drugs work by stopping overactive proteins that cause disease. The leukemia drug Gleevec, for example, is a small-molecule inhibitor (antagonist) of the protein Bcr-Abl, whose overactivity promotes excessive cell division. Humira...
New Muscle In The Fight Against DMD Last week’s biotech headlines lit up with the FDA’s unexpected approval of Sarepta Therapeutics’ (Cambridge, MA) newest Duchenne muscular dystrophy (DMD) drug, Vyondys 53. The FDA changed course after rejecting the product in August...
Controlling A Killer, One Step At A time Last week, we reviewed the lifecycle of the human immunodeficiency virus (HIV). Learning how the virus grows and develops has been crucial to developing medicines that control HIV infection. This knowledge has enabled drug...
World AIDS Day: Understanding HIV December 1 marked World AIDS Day, an international day dedicated to raising awareness of the AIDS pandemic caused by the spread of human immunodeficiency virus (HIV) infection. According to UNAIDS, 37.9 million people globally were...
From startups to the Fortune 500, we train employees at companies of all sizes. We offer customized, in-house courses and open enrollment classes. Visit Biotech Primer for more information.
